NCT07026110 Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
| NCT ID | NCT07026110 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RenJi Hospital |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-12-23 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-12-23 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to explore the efficacy of Trop2, EpCAM-specific PET/CT imaging for noninvasive visualization of Trop2 or EpCAM expression levels in non-small cell lung cancer; and to explore the differences between novel target-specific PET/CT examinations and conventional 18F-FDG PET/CT in the diagnosis and differential diagnosis of solid lung nodules.
Eligibility Criteria
Inclusion Criteria: 1. Age 18-80 years; 2. Imaging studies suspecting non-small cell lung cancer; 3. Solid lung nodules (≥8 mm in diameter) diagnosed by chest ct, which are subject to 18F-FDG PET/CT and surgical resection/biopsy of lung nodules according to the NCCN guideline specifications for NSCLC in the 2024 edition; 4. Patients or family members agreed to participate in this clinical study and signed an informed consent form. Exclusion Criteria: 1. Women during pregnancy and lactation; 2. Persons with a history of surgery and trauma that significantly affects metabolic distribution and anatomical structure; 3. Persons with severe other systemic diseases or known hypersensitivity to humanized monoclonal antibody products; 4. Patient is unable to cooperate in completing the PET/CT examination; 5. Patient has participated in other clinical studies within the past year that have resulted in radiation exposures in excess of an effective dose of 50 mSv, in addition to the radiation exposures anticipated from participation in this clinical study; 6. Patient should not participate in this clinical trial in the opinion of the investigator.
Contact & Investigator
Weijun Wei
STUDY CHAIR
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Frequently Asked Questions
Who can join the NCT07026110 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07026110 currently recruiting?
Yes, NCT07026110 is actively recruiting participants. Contact the research team at wwei@shsmu.edu.cn for enrollment information.
Where is the NCT07026110 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07026110 clinical trial?
NCT07026110 is sponsored by RenJi Hospital. The principal investigator is Weijun Wei at Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.